Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances

Agios Pharmaceuticals AGIO executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in thalassemia and a recently submitted supplemental new drug application for sickle cell disease during a presentation at the 2026 RBC Capital Markets Global Healthcare Conference.

Brian Goff, Agios’ chief executive officer, said the company has had “a really great start to 2026,” citing the launch of AQVESME, the brand name for mitapivat in thalassemia, and the filing of an sNDA with the U.S. Food and Drug Administration for mitapivat in sickle cell disease.